Evoke Pharma (EVOK) Stock Price, News & Analysis

Company Overview

Evoke Pharma, Inc. is a clinical-stage specialty pharmaceutical company focused on developing novel therapies for gastrointestinal (GI) motility disorders. The company’s lead product candidate, relamorelin, is a selective ghrelin receptor agonist designed to restore gastric motility and accelerate gastric emptying in conditions such as diabetic gastroparesis. Relamorelin has been granted orphan drug designation by the U.S. Food and Drug Administration and has demonstrated proof-of-concept activity in multiple clinical trials, positioning it as a promising treatment for patients with impaired GI function.

In addition to relamorelin, Evoke Pharma is advancing earlier-stage programs targeting metabolic and GI conditions, leveraging its expertise in peptide chemistry and receptor pharmacology. The company’s research efforts aim to extend the therapeutic potential of ghrelin receptor modulation into related indications, including postoperative ileus and chronic constipation. Evoke collaborates with academic and industry partners to optimize its pipeline and expand clinical development into new patient populations.

Founded in 2006 and headquartered in San Diego, California, Evoke Pharma completed its initial public offering on the Nasdaq under the ticker EVOK. The company serves patients across the United States and is exploring opportunities to establish international partnerships for broader market access. Evoke’s leadership team combines decades of experience in gastroenterology drug development, regulatory affairs and commercial strategy to advance its mission of improving quality of life for individuals with debilitating GI disorders.

Key Stats

• Today's Range: $4.41 to $4.73
• 50-Day Range: $4.46 to $6.34
• 52-Week Range: $1.94 to $12.32
• Volume: 46,077 shs
• Average Volume: 30,124 shs
• Market Capitalization: $6.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Evoke Pharma Stock Analysis - MarketRank™

Evoke Pharma scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Evoke Pharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Evoke Pharma is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evoke Pharma is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evoke Pharma has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.92% of the float of Evoke Pharma has been sold short.

Short Interest Ratio / Days to Cover

Evoke Pharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evoke Pharma has recently decreased by 35.59%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evoke Pharma does not currently pay a dividend.

Dividend Growth

Evoke Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.92% of the float of Evoke Pharma has been sold short.

Short Interest Ratio / Days to Cover

Evoke Pharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evoke Pharma has recently decreased by 35.59%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Evoke Pharma this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evoke Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.29% of the stock of Evoke Pharma is held by insiders.

EVOK Stock Analysis - Frequently Asked Questions

How have EVOK shares performed this year?

Evoke Pharma's stock was trading at $4.42 at the start of the year. Since then, EVOK stock has increased by 0.9% and is now trading at $4.46.

How were Evoke Pharma's earnings last quarter?

Evoke Pharma, Inc. (NASDAQ:EVOK) posted its quarterly earnings data on Thursday, August, 14th. The specialty pharmaceutical company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.32. The specialty pharmaceutical company had revenue of $3.75 million for the quarter, compared to analyst estimates of $3.80 million. Evoke Pharma had a negative trailing twelve-month return on equity of 99.48% and a negative net margin of 42.07%.

When did Evoke Pharma's stock split?

Evoke Pharma's stock reverse split on Thursday, August 1st 2024.The 1-12 reverse split was announced on Thursday, August 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Evoke Pharma?

Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Evoke Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evoke Pharma investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/17/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - GENERIC DRG
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EVOK
• CIK: 1403708
• Web: www.evokepharma.com
• Phone: (858) 345-1494
• Fax: N/A
• Employees: 4
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): ($2.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.35 million
• Net Margins: -42.07%
• Pretax Margin: -42.07%
• Return on Equity: -99.48%
• Return on Assets: -33.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.37
• Quick Ratio: 1.32

Sales & Book Value

• Annual Sales: $10.25 million
• Price / Sales: 0.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.74 per share
• Price / Book: 0.94

Miscellaneous

• Outstanding Shares: 1,560,000
• Free Float: 1,523,000
• Market Cap: $6.96 million
• Optionable: Not Optionable
• Beta: -0.10